AVEFF.US Avecho Biotechnology Limited
- Market cap
- USD 17.4M
- P/E
- -
- P/B
- 1.33x
- ROE
- -403.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AVEFF.US undervalued?
Graham numberThe Graham number of Avecho Biotechnology Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avecho Biotechnology Limited fundamental analysis
No fundamental analysis for Avecho Biotechnology Limited yet.
Avecho Biotechnology Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical produc…
Full company profileAvecho Biotechnology Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avecho Biotechnology Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.59M | 1.15M | 1.25M | 4.24M | 385K | 794K | 1.21M | 474K | 1.29M | 1.24M | 238K |
| Gross Profit | 1.26M | 1.06M | 699K | 4.02M | 241K | 508K | 870K | -43.8K | 833K | 751K | -43.1K |
| Operating Income | -9.29M | -9.06M | -5.17M | 1.57M | -3.41M | -4.55M | -3.06M | -4.59M | -4.80M | -6.00M | -13.0M |
| EBITDA | -9.56M | -9.04M | -4.60M | 1.54M | -2.09M | -2.98M | -2.11M | -3.24M | -2.92M | -5.86M | -12.8M |
| Net Income | -17.3M | -8.55M | -3.99M | 850K | -2.64M | -3.42M | -2.34M | -3.44M | -3.12M | -4.41M | -7.68M |
| EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 13.4M | 8.24M | 4.80M | 5.32M | 3.35M | 5.25M | 3.35M | 7.32M | 5.00M | 7.10M | 8.40M |
| Total Liabilities | 1.71M | 1.84M | 902K | 556K | 700K | 709K | 921K | 942K | 1.73M | 5.54M | 6.49M |
| Shareholders' Equity | 11.6M | 6.40M | 3.90M | 4.76M | 2.65M | 4.54M | 2.42M | 6.38M | 3.27M | 1.56M | 1.90M |
| Cash & Short-term Investments | 6.09M | 2.90M | 2.11M | 3.21M | 1.87M | 3.26M | 1.47M | 5.50M | 2.37M | 4.66M | 6.60M |
| Total Debt | - | - | - | 97.2K | 166K | 93.9K | 246K | 175K | 1.08M | 14.5K | 227K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.24M | -6.39M | -2.15M | 1.19M | -1.42M | -3.10M | -1.67M | -3.18M | -3.97M | 1.10M | -198K |
| Capital Expenditure | 62.0K | 55.6K | 424.00 | 5.15K | 5.15K | 203K | 53.1K | 0.00 | 0.00 | 0.00 | 8.00K |
| Free Cash Flow | -6.30M | -6.44M | -2.15M | 1.19M | -1.43M | -3.30M | -1.72M | -3.18M | -3.97M | 1.10M | -206K |
| Ratios | |||||||||||
| ROE | -148.7% | -133.4% | -102.3% | 17.9% | -99.3% | -75.3% | -96.6% | -53.9% | -95.5% | -283.2% | -403.4% |
| ROA | -129.7% | -103.7% | -83.1% | 16.0% | -78.5% | -65.1% | -70.0% | -47.0% | -62.5% | -62.2% | -91.5% |
| Net Profit Margin | -1,090.3% | -743.0% | -318.8% | 20.1% | -685.1% | -430.4% | -194.2% | -725.8% | -241.3% | -356.8% | -3,227.5% |
| Debt to Equity | - | - | - | 0.02x | 0.06x | 0.02x | 0.10x | 0.03x | 0.33x | 0.01x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avecho Biotechnology Limited dividends
Avecho Biotechnology Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 85:83 on Nov 21, 2022.
Who owns Avecho Biotechnology Limited
- Insiders 27.02%
- Institutions 0.00%
- Public & others 72.98%
- Shares outstanding 3.86B
- Free float 2.45B
Avecho Biotechnology Limited company profile
- Company name
- Avecho Biotechnology Limited
- Ticker
- AVEFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Hallmarc Business Park, Clayton, VIC, Australia, 3168
- Phone
- 61 3 9002 5000
- Website
- avecho.com.au
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Avecho Biotechnology Limited management
3- Dr. Paul Gavin BSc (Hons), Ph.D.Chief Executive Officer
- Dr. Roksan Libinaki Ph.D.Chief Operating Officer
- Ms. Naomi LawrieCompany Secretary